论文部分内容阅读
目的:观察丹参川芎嗪注射液治疗急性脑梗死患者临床疗效。方法:急性脑梗死患者60例,随机分为观察组和对照组各30例。对照组给予低分子右旋糖酐、改用5%葡萄糖+复方丹参注射液、阿司匹林。观察组在对照组治疗基础上,去复方丹参注射液,改用5%葡萄糖+丹参川芎嗪注射液。2组均治疗2周。观察临床疗效及残疾程度量表(MRS),美国国立卫生研究院卒中量表(NIHSS)评分和日常生活活动能力(Barthel,BI)评分。结果:临床总有效率观察组83.34%,对照组66.67%,2组比较,差异有统计学意义(P<0.05)。2组治疗后NIHSS评分、BI评分均有改善,与本组治疗前比较,差异有统计学意义(P<0.05);治疗后观察组NIHSS评分、BI评分显著高于对照组,与对照组比较,差异有统计学意义(P<0.05)。MRS评分观察组无症状、中重度残疾例数与对照组比较,差异均有统计学意义(P<0.05)。结论:丹参川芎嗪注射液对急性脑梗死患者神经功能缺损的治疗有较好的效果,可促进患者脑神经功能的恢复和预后的康复。
Objective: To observe the clinical effect of ligustrazine injection in the treatment of acute cerebral infarction. Methods: 60 patients with acute cerebral infarction were randomly divided into observation group and control group, 30 cases each. The control group was given low molecular dextran, switch to 5% glucose + compound Danshen injection, aspirin. Observation group in the control group based on the treatment, to compound Danshen injection, switch to 5% glucose + Salvia Ligustrazine injection. 2 groups were treated for 2 weeks. The clinical efficacy and disability scale (MRS), NIHSS score and Barthel (BI) score were observed. Results: The total clinical effective rate was 83.34% in the observation group and 66.67% in the control group. There was significant difference between the two groups (P <0.05). The scores of NIHSS and BI in both groups were improved after treatment, which were significantly different from those before treatment (P <0.05). After treatment, the NIHSS and BI scores in the observation group were significantly higher than those in the control group , The difference was statistically significant (P <0.05). There was significant difference between the MRS score observation group and the control group in asymptomatic and moderate-severe disability cases (P <0.05). Conclusion: Salviae miltiorrhizae ligustrazine injection has a good effect on the treatment of neurological deficits in patients with acute cerebral infarction, which can promote the recovery of neurological function and prognosis of patients.